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Background: Tenascin-C (TNC), an extracellular matrix glycoprotein, is expressed transiently in distinct areas in
association with active tissue remodeling. This study aimed to explore how ischemic postconditioning (PC) affects
myocardial expression of TNC and ventricular remodeling using 125I-labeled anti-TNC antibody (125I-TNC-Ab) in a rat
model of ischemia and reperfusion.
Methods: In control rats (n = 27), the left coronary artery (LCA) was occluded for 30 min followed by reperfusion for
1, 3, 7, and 14 days. PC (n = 27) was performed just after the reperfusion. At the time of the study, 125I-TNC-Ab (1.0
to 2.5 MBq) was injected. Six to 9 h later, to verify the area at risk, 99mTc-MIBI (100 to 200 MBq) was injected
intravenously just after the LCA reocclusion, with the rats sacrificed 1 min later. Dual tracer autoradiography was
performed to assess 125I-TNC-Ab uptake and area at risk. To examine the ventricular remodeling, echocardiography was
performed 2 M after reperfusion in both groups.
Results: In control rats, 125I-TNC-Ab uptake ratio at 1 day after reperfusion was 3.73 ± 0.71 and increased at 3 days
(4.65 ± 0.87), followed by a significant reduction at 7 days (2.91 ± 0.55, P < 0.005 vs 3 days) and14 days (2.01 ± 0.17,
P < 0.005 vs 1 and 3 days). PC attenuated the 125I-TNC-Ab uptake throughout the reperfusion time from 1 to 14
days; 2.59 ± 0.59 at 1 day, P < 0.05: 3.10 ± 0.42 at 3 days, P < 0.005: 1.93 ± 0.37 at 7 days, P < 0.05: 1.40 ± 0.07 at 14
days, P < 0.001. In echocardiography, PC reduced the ventricular end-diastolic and systolic dimensions (1.00 ± 0.06
cm to 0.83 ± 0.14 cm (P < 0.05) and 0.90 ± 0.15 cm to 0.62 ± 0.19 cm (P < 0.05), respectively) and prevented a decline of
ventricular percentage fractional shortening (10.5 ± 3.7 to 28.2 ± 10.7, P < 0.005).
Conclusions: These data indicate that 125I-TNC-Ab imaging may be a way to monitor myocardial injury, the
subsequent repair process, and its response to novel therapeutic interventions like PC by visualizing TNC expression.
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Extracellular matrix, in addition to cardiac cells, is es-
sential to maintain the integrity of cardiac tissue and
plays an important role not only in providing structural
and mechanical support but also in modulating cell
function. Cardiac repair after myocardial infarction is
regulated through activation and suppression of the* Correspondence: taki@med.kanazawa-u.ac.jp
1Department of Nuclear Medicine, Kanazawa University Hospital, 13-1
Takara-machi, Kanazawa 920-8641, Japan
Full list of author information is available at the end of the article
© 2015 Taki et al.; licensee Springer. This is an
Attribution License (http://creativecommons.or
in any medium, provided the original work is pacute inflammatory process. Necrosis of cardiomyocytes
provokes acute inflammation to remove dead cells and
matrix debris, followed by timely infiltration of the in-
farcted myocardium with myofibroblasts. These secrete
large amounts of extracellular matrix proteins, leading
to replacement of myocardial dropout with mature
collagen-based scar tissue in the infarct. These inflam-
matory and fibrotic processes are critically involved in
the pathogenesis of ventricular remodeling, which is
accompanied by changes in the structure and compos-
ition of the extracellular matrix and is a significantOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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prognosis [1].
Tenascin-C (TNC), an extracellular matrix glycopro-
tein, could provide important biological signaling that
influences cell motility, proliferation, differentiation, sur-
vival, or apoptosis via cell-extracellular matrix inter-
action during tissue remodeling of various tissues [2,3].
TNC appears in the heart only in the early stages of em-
bryonic development and is not normally expressed in
the adult. However, it reappears transiently associated
with myocardial injury such as myocardial infarction
[4,5], hibernating myocardium [6], myocarditis [7-9],
and dilated cardiomyopathy [10,11]. Its site-specific ex-
pression suggests that TNC plays important roles during
tissue remodeling but also that it can serve as an indica-
tor of myocardial disease activity.
Recently, other groups and we have reported increased
serum TNC in heart failure patients, reflecting the sever-
ity and progression of ventricular remodeling [12-15].
Of particular interest is that serum levels of TNC within
1 week of infarction can be a possible predictor of ven-
tricular remodeling and poor prognosis [16,17]. Also,
our previous study implied that TNC expression might
be altered if the ischemic insults were modified by cardi-
oprotective interventions [18].
Postconditioning, defined as several repeated cycles of
intermittent reperfusion and reocclusion after an index
ischemia, is cardioprotective in a canine model of ische-
mia and reperfusion [19]. However, the effect of post-
conditioning on the TNC expression and left ventricular
remodeling is unspecified. This prompted us to explore
the effect of postconditioning on the spatial and tem-
poral changes occurring in the expression of TNC after
myocardial ischemia and reperfusion using 125I-labeled
anti-tenascin-C antibody (125I-TNC-Ab) and left ven-
tricular remodeling in a rat model of acute ischemia and
reperfusion.
Methods
Animal model of acute ischemia and reperfusion
All experimental procedures involving animals were con-
ducted in accordance with the institutional guidelines set
by the Institute for Experimental Animals, Kanazawa
University Advanced Science Research Center. Eight to
11-week-old male Wistar rats (n = 54) were anesthe-
tized with an intraperitoneal administration of 40 mg of
pentobarbital per kilogram and ventilated mechanically
with room air. After left thoracotomy and exposure of
the heart, a 7-0 polypropylene suture on a small curved
needle was passed through the myocardium beneath
the proximal portion of the left coronary artery (LCA),
and both ends of the suture were passed through a
small vinyl tube to make a snare. The suture material
was pulled tight against the vinyl tube to occlude theLCA. Myocardial ischemia was confirmed by regional
cyanosis of the myocardial surface and ST-segment ele-
vation on the ECG. In control rats, LCA was occluded
for 30 min and reperfusion was obtained by release of
the snare and confirmed by the finding of a myocardial
blush over the area at risk. In the group of rats with
postconditioning, after the 30 min of LCA occlusion,
10 s of reperfusion followed by 10 s of LCA reocclusion
was repeated six times at the beginning of the reperfu-
sion. The snare was left loose on the surface of the
heart for reocclusion of the LCA just before sacrifice to
identify the area at risk (18). Groups of animals with
and without postconditioning were studied at 1 (n = 5,
5), 3 (n = 6, 5), 7 (n = 4, 6), and 14 days (n = 6, 5, re-
spectively) after reperfusion. At the time of the study,
125I-TNC-Ab (1.0 to 2.5 MBq) was administered via a
tail vein. Six to 9 h afterward, 100 to 200 MBq of
99mTc-MIBI was injected via a tail vein just after the
reocclusion of the proximal portion of the LCA for de-
lineation of the area at risk. One minute later, the rat
was euthanized and the heart was removed for analysis.
The excised heart was rinsed in saline, frozen in isopen-
tane, cooled in dry ice, and embedded in methyl cellu-
lose. Serial short-axis heart sections 20 μm thick were
obtained by sectioning on a cryostat to create a series
of rings for autoradiography.
To evaluate the left ventricular remodeling 2 months
after reperfusion, 30 min of LCA occlusion followed by
reperfusion with (n = 6) and without postconditioning
(n = 6) was performed. Two months later, echocardiog-
raphy was performed to evaluate the left ventricular di-
mensions and function. After echocardiography, 100 to
200 MBq of 99mTc-MIBI was injected via a tail vein. One
minute later, the rat was euthanized and the heart was
removed for autoradiography.
Radiolabeling of anti-tenascin-C antibody
Anti-TNC mouse IgG Fab’, a mouse monoclonal antibody
against TNC, clone 4F10TT, was raised by immunization
of a TNC-null mouse with purified human TNC as de-
scribed previously [7].
Radiolabeling of anti-TNC antibody with 125I was
achieved by the chloramine-T method [20]. Briefly, [125I]
sodium iodide solution (37 MBq/10 μL, Perkin Elmer,
Waltham, MA) was added to 60 μL of antibody in PBS
(0.32 mg/mL). Following mixing, 4 μL of chloramine-T
aqueous solution (1 mg/mL) was added. After 15 min at
room temperature, the reaction was quenched with 20
μL of Na2H2SO5. The crude product was purified with a
PD-10 column (GE Healthcare UK Ltd., Buckingham-
shire, England) with saline as the eluate. The radiochem-
ical purity of 125I-TNC-Ab was determined by thin layer
chromatography (TLC). TLC analyses were performed
with silica plates (Art 5553, Merck, Darmstadt, Germany)
Taki et al. EJNMMI Research  (2015) 5:21 Page 3 of 9with saline as the developing solvent. Radiochemical pur-
ity was defined as the percent protein-bound activity,
which was assessed by dividing the counts at the TLC ori-
gin by the total TLC counts. Specificity of the 125I-TNC-
Ab was approved by the autoradiography with 125I-labeled
nonspecific antibody in the previous study [18].
Dual-tracer autoradiography
Dual tracer autoradiography of the left ventricular short
axis slices was performed for the assessment of 125I-TNC-
Ab uptake and ischemic area (or area at risk) demon-
strated by 99mTc-MIBI image. The first autoradiographic
exposure on an imaging plate (BAS-MS, Fuji Film) was
performed for 15 to 20 min to visualize the area at risk
expressed by 99mTc-MIBI distribution at 1 to 2 h after sac-
rifice. Three days later (12 half-lives of 99mTc), the second
exposure was made for 7 days to image the distribution of
125I-TNC-Ab.
Data analysis
125I-TNC-Ab accumulation was evaluated in three myo-
cardial slices at the mid-ventricular level spaced 1 mm
apart. The distribution of the tracers was determined by
analysis of the digitized autoradiographs. The photosti-
mulated luminescence in each pixel (100 × 100 μm) was
determined using a bioimaging analyzer (BAS-5000, Fuji
Film). For quantitative analysis, the uptake values of
each region of interest (ROI) were expressed as the
background-corrected photostimulated luminescence
per unit area (1 mm2). A background ROI was set adja-
cent to the left ventricle. Ischemic and normally perfused
areas were defined from the 99mTc-MIBI image, and these
ROIs were applied to the 125I-TNC-Ab images to evaluate
the uptake of 125I-TNC-Ab. 125I-TNC-Ab uptake area was
also set manually as a ROI by circumscribing the in-
creased activity of the 125I-TNC-Ab. 125I-TNC-Ab uptake
ratio was calculated by dividing the uptake value in an is-
chemic area by that of a normally perfused area. The ratio
of 125I-TNC-Ab uptake ROI area to an ischemic ROI area
was defined as the percentage of the 125I-TNC-Ab uptake
area. All parameters in each rat were expressed as the
average value obtained from the analysis of three repre-
sentative slices.
The autoradiography in rats just administered 99mTc-
MIBI after echocardiography 2 months after ischemia,
and reperfusion was analyzed for myocardial viability.
Area of infarction was defined arbitrarily with less than
60% of maximal 99mTc-MIBI uptakes in the three repre-
sentative slices.
Immunohistochemical staining
Short axis frozen sections adjacent to the slices for auto-
radiography were mounted on slides. These short axial
heart sections were washed with PBS and stained withmouse monoclonal anti-TNC mouse 4F10TT, the same
antibody used for autoradiography, with direct immuno-
peroxidase technique. For paraffin sections, the heart
was fixed in 4% paraformaldehyde, embedded in paraffin,
and immunostained as previously described [5]. Briefly,
after treatment with pepsin for 10 min for antigen re-
trieval, sections were incubated with anti-TNC antibody
4F10TT and subsequently with peroxidase-conjugated
anti-mouse IgG Fab’ (Medical and Biological Lab Co.
Ltd., Nagoya, Japan). After washing, diaminobenzidine/
H2O2 solution was used to demonstrate antibody bind-
ing. The site and distribution of the expression of the
TNC was examined with the aid of the hematoxylin-
eosin stained slice adjacent to the immunohistochemical
stained slice.
Echocardiography
Echocardiography was performed in rats with (n = 6)
and without (n = 6) postconditioning at 2 months after
ischemia and reperfusion under anesthesia with 1% to
2% isoflurane using Vivid 7 (GE Healthcare, Milwaukee,
WI, USA) with a 14-MHz i13L linear array transducer.
Three cardiac cycles of the parasternal short axis view at
papillary muscle level were recorded at a frame rate of
265 per second. The images were processed offline using
commercially available software (EchoPac 6.1, GE Health-
care, Milwaukee, WI, USA). The left ventricular internal
dimensions at the end of diastole (LVEDD) and at the end
of systole (LVESD) were measured digitally using anatom-
ical M-mode feature. LV fractional shortening (%FS) was
calculated as [(LVEDD–LVESD)/LVEDD] × 100.
Statistical analysis
All results were expressed as mean ± 1 SD. Statistical
analyses were performed using a Macintosh computer
with software JMP 5.0.1 J. Group comparisons were per-
formed using Tukey-Kramer method to identify differ-




125I-labeled anti-TNC antibody was prepared with high
radiochemical yield (89%). After purification by PD-10,
125I-labeled anti-TNC antibody showed a radiochemical
purity of over 99%.
Size of area with 125I-TNC-Ab uptake against area at risk
The percentages of 125I-TNC-Ab uptake areas against area
at risk in rats without postconditioning at 1, 3, 7, and 14
days after reperfusion tended to decline over time (82.7% ±
8.6%, 70.6% ± 20.5%, 61.1% ± 15.1%, 63.8% ± 5.6%, re-
spectively, P = ns) (Figure 1).
Figure 1 Time course of the percentages of 125I-TNC-Ab uptake area against area at risk (percentage area). The percentages of 125I-TNC-Ab
uptake areas without postconditioning at 1, 3, 7, and 14 days after reperfusion tended to decline over time but the differences were statistically
insignificant (82.7% ± 8.6%, 70.6% ± 20.5%, 61.1% ± 15.1%, 63.8% ± 5.6%, respectively, P = ns). Postconditioning reduced the percentages of 125I-TNC-Ab
uptake areas at all reperfusion times (at 1, 3, 7, and 14 days after reperfusion were 69.1% ± 6.6%, 65.9% ± 6.1%, 55.7% ± 6.5%, and 54.4% ± 3.5%,
respectively) but not statistically significantly so (P = ns, vs without postconditioning).
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Ab uptake areas against area at risk at all reperfusion
times (values at 1, 3, 7, and 14 days after reperfusion were
69.1% ± 6.6%, 65.9% ± 6.1%, 55.7% ± 6.5%, and 54.4% ±
3.5%, respectively), with these differences not statisti-
cally significant (P = ns, vs without postconditioning)
(Figure 1).125I-TNC-Ab Uptake
In visual analysis, strong 125I-TNC-Ab uptake was ob-
served in the area at risk at 1 and 3 days after reperfu-
sion, followed by moderate uptake at 7 and 14 days after
reperfusion. Postconditioning attenuated the 125I-TNC-
Ab uptake throughout the course of reperfusion time
(Figure 2).
In the quantitative analysis, 125I-TNC-Ab uptake ratio
of the rats without postconditioning at 1 day after reper-
fusion was 3.73 ± 0.71 and increased at 3 days (4.65 ±
0.87), followed by a significant reduction at 7 days after
reperfusion (2.91 ± 0.55, P < 0.005 vs 3 days) and followed
by further reduction at 14 days (2.01 ± 0.17, P < 0.005 vs 1
and 3 days).
Postconditioning reduced the 125I-TNC-Ab uptake ra-
tio throughout the time from 1 to 14 days after reperfu-
sion; 2.59 ± 0.59 at 1 day, P < 0.05: 3.10 ± 0.42 at 3 days,
P < 0.005: 1.93 ± 0.37 at 7 days, P < 0.05, 1.40 ± 0.07 at 14
days, P < 0.001 (Figure 3).Histopathological findings
At 1 to 3 days after ischemia and reperfusion, muscle
lysis, muscle destruction, and coagulation necrosis of
cardiomyocytes with severe inflammatory cell infiltration
were observed in the infarcted area. TNC deposition was
observed throughout the infarcted area with inflamma-
tion, though strong staining was limited to the border
zone between infracted and intact areas. No TNC expres-
sion was detected in the intact area. This TNC expression
pattern was not changed significantly by postconditioning,
but staining of TNC tended to be weaker in both border
zone and infarcted area. Then, necrotic tissue was grad-
ually replaced by granulation tissue with attenuation of
inflammation. TNC deposition gradually decreased
until day 14. With postconditioning, the spatiotemporal
pattern of TNC deposition came to resemble that of
control animals, while the degree of staining became
weaker (Figure 4).Left ventricular remodeling at 2 months after reperfusion
Echocardiographic data at 2 months after ischemia and
reperfusion are given in Figure 4. Heart rate in control
rats and postconditioning was similar (389 ± 8.7/min and
401 ± 32/min, respectively, P = 0.40). Postconditioning
reduced the LVEDD (1.00 ± 0.063 cm to 0.83 ± 0.14 cm,
P < 0.05) (Figure 5a) and LVESD (0.90 ± 0.15 cm to 0.62 ±
0.19 cm, P < 0.05) (Figure 5b). Postconditioning also
1 d           3 d           7 d         14 d 







Figure 2 Autoradiographies of 125I-TNC-Ab and 99mTc-MIBI in rats with and without postconditioning. Intense 125I-TNC-Ab uptake was
observed in the area at risk that was represented by the perfusion defect of 99mTc-MIBI at 1 and 3 days after reperfusion, followed by moderate
uptake at 7 and 14 days after reperfusion. Postconditioning attenuated the 125I-TNC-Ab uptake at all reperfusion times.
Figure 3 Comparison between the 125I-TNC-Ab uptake ratios in rats with and without postconditioning. 125I-TNC-Ab uptake ratio was
calculated by dividing the 125I-TNC-Ab count density in the area at risk by that of non-ischemic area. 125I-TNC-Ab uptake ratio in rats without
postconditioning at 1 day after reperfusion was 3.73 ± 0.71 and increased at 3 days (4.65 ± 0.87), followed by a significant reduction at 7 days
after reperfusion (2.91 ± 0.55, P < 0.005 vs 3 days) and a further reduction at 14 days (2.01 ± 0.17, P < 0.005 vs 1 and 3 days). Postconditioning
attenuated the 125I-TNC-Ab uptake ratio throughout the reperfusion time from 1 to 14 days; 2.59 ± 0.59 at 1 day, P < 0.05: 3.10 ± 0.42 at 3 days,
P < 0.005: 1.93 ± 0.37 at 7 days, P < 0.05, 1.40 ± 0.07 at 14 days, P < 0.001.


















Figure 4 Immunostaining for TNC at 3, 7, and 14 days after reperfusion with and without postconditioning is presented. Strong TNC
brown staining was seen in border zone between intact and infarcted area, and also scattered brown staining was seen throughout the infarcted
area at 3 days after reperfusion. With postconditioning, TNC staining tended to be weaker in both border zone and infarcted area. At 7 and 14
days after reperfusion, TNC staining became weaker at both border zone and infarcted area. With postconditioning, TNC staining at both border
zone and infarcted area became weaker. Intact, intact area; Inf, infarcted area; Scale bars, 100 μm.
Taki et al. EJNMMI Research  (2015) 5:21 Page 6 of 9mitigated the left ventricular dysfunction (%FS; 10.5% ±
3.7% to 28.2% ± 10.7%, P < 0.005) (Figure 5c). Infarct
size (percentage of left ventricle) by autoradiography in
rats with postconditioning was significantly smaller
than those without postconditioning (44.5% ± 7.9% vs
59.7% ± 9.0%, P < 0.05).
Discussion
The present study revealed that ischemic postcondi-
tioning significantly attenuated TNC expression as















Control          Poscon Control  
Figure 5 Echocardiographic data 2 months after reperfusion in rats w
postconditioning significantly reduced the LVEDD (A) (P < 0.05), LVESV (B)
mean values, and bars show standard deviation. LVEDD, left ventricular diasto
of fractional shortening; Poscon, postconditioning.throughout the entire period until 2 weeks after ische-
mia and reperfusion.
Postconditioning also attenuated left ventricular re-
modeling and reduced infarct size at 2 months after is-
chemia and reperfusion. These data suggest that
attenuation of TNC expression during the acute to
subacute phase of tissue healing after infarction by
postconditioning might be related to the attenuation of
ventricular remodeling at 2 months after myocardial
infarction, although whether the relationship is cause





        Poscon Control          Poscon
ith and without postconditioning. Compared with control rats,
(P < 0.05), and improved %FS (C) (P < 0.005). Small squares indicate the
lic dimension; LVESD, left ventricular systolic dimension; %FS, percentage
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postconditioning defined as rapid sequential intermittent
interruption of blood flow applied during early moments
of reperfusion in a canine model of 60 min of myocar-
dial ischemia and reperfusion [19], the cardio-protective
effect induced by postconditioning has been extensively
investigated and confirmed in many species, including
man [21]. The attenuation of cardiac injury afforded by
postconditioning has been attributed to suppression of
reperfusion injury with consequent attenuation of myo-
cardial apoptosis and necrosis. Many of the primary
physiological endpoints of protection during reperfusion
have been investigated including delay in washout of
endogeneous autacoids, reduction of inflammatory re-
sponse, protection of vascular endothelium, stimulation
of survival kinase and transmitter, inhibition of death
kinase, preservation of mitochondrial function, and re-
duction of cardiomyocyte loss [21]. Although a number
of protective mechanisms targeted by postconditioning
have been explored, it is generally recognized that inhib-
ition of mitochondrial permeability transition pore open-
ing by postconditioning is the final step in a complicated
series of cellular events responsible for cell protection
[21-23]. After 30-m ischemia of the isolated rat heart,
mitochondrial permeability transition pore opening does
not occur during ischemia but does within the first 5 m
of reflow [24]. Therefore, it is important to induce post-
conditioning just after reperfusion to inhibit mitochon-
drial permeability transition pore opening, at which time
its effect on the reduction of tissue damage has been
demonstrated.
On the other hand, the effect of postconditioning on
tissue repair including interstitial signaling and remodel-
ing has been scarcely investigated. After myocardial in-
farction in the permanent ligation model, TNC is
markedly but transiently upregulated during the early
phase of tissue repair, is predominantly produced by
interstitial fibroblasts in the vicinity of the injured cardi-
omyocytes but not by cardiomyocytes themselves [25],
and is localized in the border zone between infarcted
and viable myocardium [4,5] while in a reperfusion
model it is scattered throughout the infarcted area in
addition to border zone [18]. TNC may exert conflicting
effects on cardiac tissue repair, healing, and ventricular
remodeling [26,27]. TNC may loosen the strong adhe-
sion of cardiomyocytes from the matrix and upregulate
the expression and activity of matrix metalloproteinases
[28,29], promoting degradation of the extracellular
matrix and slippage of myocytes and facilitate inflamma-
tory cell infiltration within the ventricular wall, resulting
in an increased risk of ventricular thinning and dilata-
tion. However, these functions promote cell rearrange-
ment and allow myofibroblasts and capillary vessels to
spread into tissue during the restoration process. Becauseof the limited regenerative ability of cardiomyocytes,
the interstitial cells become a major player in myocar-
dial tissue repair, with especially myofibroblasts playing
an important role in wound healing by synthesizing col-
lagens and exerting strong contractile forces to pro-
mote wound healing [30]. It is suggested that TNC
produced by interstitial cells at an early phase of myo-
cardial infarction promotes recruitment of myofibro-
blasts to injured sites by accelerating migration and
differentiation and enhancing traction forces [25].
Therefore, these functions of TNC may facilitate tissue
healing, reinforcement of the cardiac matrix, and fibro-
sis and prevent ventricular dilatation by generating
traction forces [5,7,25].
Although it is difficult to conclude whether TNC is
more beneficial or detrimental for tissue healing and re-
construction after myocardial infarction, a timely and
proper degree of TNC expression might be beneficial for
myocardial tissue repair, whereas prolonged overexpres-
sion of TNC might interfere with sound tissue repair
and cause inappropriate reconstruction of infarcted ven-
tricle, resulting in so-called ventricular remodeling.
In the mice model of permanent ligation of the coron-
ary artery, ventricular remodeling in the TNC knockout
mouse was significantly reduced and cardiac function
was improved compared with the wild type at day 28
after myocardial infarction [31]. In patients with acute
myocardial infarction, peak serum TNC level at 5 days
after infarction is an important independent predictor of
prognosis, and higher TNC level is associated with a
greater risk of left ventricular remodeling at 6 months
after infarction, indicating that overexpression of TNC
may aggravate ventricular remodeling [16]. The results
of the present study were consistent with those of these
animal and human studies in that less TNC expression
due to postconditioning was found to be associated with
less ventricular remodeling.
The application of target radionuclide imaging of re-
gional TNC expression as proposed in the present study
holds the potential to quantify the extent, amount, and
localization of TNC expression and relate the pathophysio-
logical events to the tissue repair and remodeling occur-
ring after severe myocardial ischemia. The current study
also demonstrated that the 125I-TNC-Ab imaging ap-
proach after myocardial ischemia and reperfusion provides
an opportunity to monitor the effect of postconditioning,
potentially leading to novel therapeutic interventions, di-
rected at the reducing the extracellular matrix remodeling
occurring after myocardial infarction.
One of the limitations of this study was that the left
ventricular function was assessed on only short axis
slices in echocardiography, because remodeling and dila-
tion mainly occur on the apical part of the ventricle after
anterior myocardial infarction.
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TNC-Ab is required. Labeling with 123I can easily be
performed in the same way as for 125I. In vivo SPECT
imaging by 111In-TNC-Ab has already been obtained
successfully at 6 h after administration of the tracer in a
rat model of 3 days after permanent coronary artery
ligation. The biodistribution study of 111In-TNC-Ab
showed that target-to-blood, target-to-lung, and target-
to-liver ratios were 3.3, 2.0, and 0.35, respectively [32].
On the other hand, our previous study demonstrated
that rapid blood clearance and retention of 125I-TNC-Ab
in the infarcted area, resulting in a decent target-to-
blood ratio (1.85 ± 0.14 at 5 h and 4.8 ± 1.0 at 24 h after
injection) and good target-to-lung ratio (1.97 ± 0.19 at
5 h and 4.9 ± 1.2 at 24 h after injection), indicate the
feasibility of in vivo imaging at 5 h or later after tracer
injection [18]. However, relatively high liver uptake re-
sulted in a low target-to-liver ratio (0.66 at 5 h and 0.82
at 24 h), suggesting that careful interpretation might be
required for myocardial uptake adjacent to the liver, al-
though the ratio was improved compared to that of
111In-TNC-Ab.Conclusions
The present study demonstrated that postconditioning at-
tenuates the whole process of TNC expression demon-
strated by 125I-TNC-Ab after myocardial ischemia and
reperfusion. Postconditioning also attenuated left ven-
tricular remodeling at 2 months after ischemia and reper-
fusion. The obtained data also implied that radiolabeled
TNC-Ab imaging may be useful as a noninvasive way to
monitor the changes occurring during the process of myo-
cardial injury and its repair by various therapeutic inter-
ventions after ischemia and reperfusion by visualizing
TNC expression.Abbreviations
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